Novartis net income 2007-2023

Novartis AG, one of the world’s top pharmaceutical companies, reported a high net income of nearly 15 billion U.S. dollars in 2023. However, two years before, the net income was even higher, at a record high 24 billion dollars.

Novartis revenue and expenses

Being a Swiss-based company, Novartis generated around one third of its revenue, namely about 15 billion U.S. dollars, in Europe in 2023. With approximately 18 billion U.S. dollars, the United States was the company's most important market in that year. Novartis AG made 31.8 billion U.S. dollars from its branded pharmaceuticals ("Promoted brands") segment that year, the company’s largest segment. Novartis spun-off its generic drugs division Sandoz in mid-2023, while eye care division Alcon was spun off in back April 2019. The company spends most of its resources on SG&A (selling, general and administration): expenses for this category reached around 12.5 billion U.S. dollars in 2023. Research and development expenditures amounted to some 11.4 billion U.S. dollars in the same year.

Novartis AG's net income from 2007 to 2023 (in billion U.S. dollars)

Characteristic	Net income in billion U.S. dollars
2023**	14.9
2022	7
2021	24
2020	8.1
2019*	11.7
2018	12.6
2017	7.7
2016	6.7
2015	17.8
2014	10.3
2013	9.3
2012	9.4
2011	9.1
2010	10
2009	8.5
2008	8.2
2007	6.5

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2024

More information

Region

Worldwide

Survey time period

2007 to 2023

Supplementary notes

This statistic was assembled from several editions of Novartis' annual report.
* During this year, eye care division Alcon was spun off and became an own company.
** During this year, generics division Sandoz was spun off and became an own company.

Open this statistic in...

French

Citation formats